The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 trial of three schedules of CUE-101 administered before surgery or chemoradiotherapy in HLA-A*0201 positive patients with HPV16+ OPSCC.
 
Jesse Meir Zaretsky
Stock and Other Ownership Interests - PACT Pharma
 
Jessica C. Ley
No Relationships to Disclose
 
Peter John Oppelt
Speakers' Bureau - Bristol Myers Squibb; Eisai; Merck
Research Funding - Enzychem Lifesciences (Inst); HiFiBiO Therapeutics (Inst); Merck (Inst)
 
Riley Mullins
No Relationships to Disclose
 
Thomas Barrett
No Relationships to Disclose
 
Ryan Jackson
Consulting or Advisory Role - Intuitive Surgical
 
Patrik Pipkorn
No Relationships to Disclose
 
Randal C Paniello
No Relationships to Disclose
 
Jason Rich
No Relationships to Disclose
 
Jingxia Liu
No Relationships to Disclose
 
Sarah Pennock
No Relationships to Disclose
 
Jared Cohen
No Relationships to Disclose
 
Wade Thorstad
Employment - Elekta (I)
 
Steven N Quayle
Employment - Cue Biopharma; Sumitomo Dainippon Pharma (I)
Stock and Other Ownership Interests - Cue Biopharma; IQVIA (I)
 
Raymond Moniz
Employment - Cue Biopharma
Stock and Other Ownership Interests - Cue Biopharma
Patents, Royalties, Other Intellectual Property - Cue Biopharma
Travel, Accommodations, Expenses - Cue Biopharma
 
Apollina Goel
No Relationships to Disclose
 
Matteo Levisetti
Employment - Cue Biopharma
Stock and Other Ownership Interests - Cue Biopharma
 
Anish Suri
Employment - Cue Biopharma
Leadership - Cue Biopharma
Stock and Other Ownership Interests - Cue Biopharma
Patents, Royalties, Other Intellectual Property - Cue Biopharma
Travel, Accommodations, Expenses - Cue Biopharma
 
Sidharth Puram
Research Funding - Cue Biopharma (Inst)
 
Douglas Adkins
Consulting or Advisory Role - Boehringer Ingelheim; Calliditas Therapeutics; CUE Biopharma; Eisai Europe; Exelixis; Genmab/Seattle Genetics; Gilead Sciences; Immunitas; Jazz Pharmaceuticals; Kura Oncology; Merck; Seagen; TargImmune Therapeutics; Vaccinex
Research Funding - Adlai Nortye (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Debiopharm Group (Inst); Epizyme (Inst); Genmab (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst)